SCHEMBL5543887

SCHEMBL5543887

CN(c1ccccc1)C1CCN(c2ccc(O)cc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ME3 Q16798 4/20 0.48
DRD4 P21917 1/20 0.44
HRH1 P35367 1/20 0.42
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.41
GAA P10253 3/20 0.41
HTR7 P34969 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ME2 P23368 2/20 0.40
ME1 P48163 2/20 0.40
NPY5R Q15761 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
DRD2 P14416 1/20 0.40
DRD3 P35462 1/20 0.40
LMNA P02545 1/20 0.40
GFER P55789 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2090519 0.85 NPY5R (0.45) ME3ALDH1A1KDM4EMAPTPKM
SCHEMBL5543880 0.85 HRH1 (0.42) HRH1NPY5RL3MBTL1DRD2DRD3
SCHEMBL5540300 0.85 HRH1 (0.42) HRH1HTR7NPY5RL3MBTL1DRD2
SCHEMBL13279467 0.83 CYP3A4 (0.54) ME3MAPTME2ME1LMNA
SCHEMBL27474246 0.81 ME3 (0.46) ME3DRD4ALDH1A1KDM4EMAPT
SCHEMBL5539933 0.80 KDM4E (0.49) ME3DRD4ALDH1A1KDM4EMAPT
SCHEMBL24782861 0.80 NOTUM (0.46) HRH1L3MBTL1DRD2DRD3
SCHEMBL2098815 0.79 CHRM4 (0.47)
SCHEMBL13281631 0.79 CHRM4 (0.47)
SCHEMBL7891539 0.77 MCHR1 (0.56) ME3DRD4ALDH1A1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ME3 146/4885DRD4 368/4885HRH1 668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.